Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Law PJ, Timofeeva M, Fernandez-Rozadilla C, Broderick P, Studd J, Fernandez-Tajes J, Farrington S, Svinti V, Palles C, Orlando G, Sud A, Holroyd A, Penegar S, Theodoratou E, Vaughan-Shaw P, Campbell H, Zgaga L, Hayward C, Campbell A, Harris S, Deary IJ, Starr J, Gatcombe L, Pinna M, Briggs S, Martin L, Jaeger E, Sharma-Oates A, East J, Leedham S, Arnold R, Johnstone E, Wang H, Kerr D, Kerr R, Maughan T, Kaplan R, Al-Tassan N, Palin K, Hänninen UA, Cajuso T, Tanskanen T, Kondelin J, Kaasinen E, Sarin AP, Eriksson JG, Rissanen H, Knekt P, Pukkala E, Jousilahti P, Salomaa V, Ripatti S, Palotie A, Renkonen-Sinisalo L, Lepistö A, Böhm J, Mecklin JP, Buchanan DD, Win AK, Hopper J, Jenkins ME, Lindor NM, Newcomb PA, Gallinger S, Duggan D, Casey G, Hoffmann P, Nöthen MM, Jöckel KH, Easton DF, Pharoah PDP, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Harkin A, Allan K, McQueen J, Paul J, Iveson T, Saunders M, Butterbach K, Chang-Claude J, Hoffmeister M, Brenner H, Kirac I, Matošević P, Hofer P, Brezina S, Gsur A, Cheadle JP, Aaltonen LA, Tomlinson I, Houlston RS, Dunlop MG.

Nat Commun. 2019 May 14;10(1):2154. doi: 10.1038/s41467-019-09775-w.

2.

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V, Briggs S, Palles C, Jaeger E, Iveson T, Kerr R, Saunders MP, Paul J, Harkin A, McQueen J, Summers MG, Johnstone E, Wang H, Gatcombe L, Maughan TS, Kaplan R, Escott-Price V, Al-Tassan NA, Meyer BF, Wakil SM, Houlston RS, Cheadle JP, Tomlinson I, Church DN.

J Natl Cancer Inst. 2019 Jan 14. doi: 10.1093/jnci/djy215. [Epub ahead of print]

3.

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.

Madi A, Fisher D, Maughan TS, Colley JP, Meade AM, Maynard J, Humphreys V, Wasan H, Adams RA, Idziaszczyk S, Harris R, Kaplan RS, Cheadle JP.

Eur J Cancer. 2018 Oct;102:31-39. doi: 10.1016/j.ejca.2018.07.009. Epub 2018 Aug 13.

PMID:
30114658
4.

Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.

Tanskanen T, van den Berg L, Välimäki N, Aavikko M, Ness-Jensen E, Hveem K, Wettergren Y, Bexe Lindskog E, Tõnisson N, Metspalu A, Silander K, Orlando G, Law PJ, Tuupanen S, Gylfe AE, Hänninen UA, Cajuso T, Kondelin J, Sarin AP, Pukkala E, Jousilahti P, Salomaa V, Ripatti S, Palotie A, Järvinen H, Renkonen-Sinisalo L, Lepistö A, Böhm J, Mecklin JP, Al-Tassan NA, Palles C, Martin L, Barclay E, Tenesa A, Farrington SM, Timofeeva MN, Meyer BF, Wakil SM, Campbell H, Smith CG, Idziaszczyk S, Maughan TS, Kaplan R, Kerr R, Kerr D, Buchanan DD, Win AK, Hopper J, Jenkins MA, Newcomb PA, Gallinger S, Conti D, Schumacher FR, Casey G, Cheadle JP, Dunlop MG, Tomlinson IP, Houlston RS, Palin K, Aaltonen LA.

Int J Cancer. 2018 Feb 1;142(3):540-546. doi: 10.1002/ijc.31076. Epub 2017 Oct 12.

5.

Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.

May-Wilson S, Sud A, Law PJ, Palin K, Tuupanen S, Gylfe A, Hänninen UA, Cajuso T, Tanskanen T, Kondelin J, Kaasinen E, Sarin AP, Eriksson JG, Rissanen H, Knekt P, Pukkala E, Jousilahti P, Salomaa V, Ripatti S, Palotie A, Renkonen-Sinisalo L, Lepistö A, Böhm J, Mecklin JP, Al-Tassan NA, Palles C, Farrington SM, Timofeeva MN, Meyer BF, Wakil SM, Campbell H, Smith CG, Idziaszczyk S, Maughan TS, Fisher D, Kerr R, Kerr D, Passarelli MN, Figueiredo JC, Buchanan DD, Win AK, Hopper JL, Jenkins MA, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Aaltonen LA, Cheadle JP, Tomlinson IP, Dunlop MG, Houlston RS.

Eur J Cancer. 2017 Oct;84:228-238. doi: 10.1016/j.ejca.2017.07.034. Epub 2017 Aug 19.

6.

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.

Rodriguez-Broadbent H, Law PJ, Sud A, Palin K, Tuupanen S, Gylfe A, Hänninen UA, Cajuso T, Tanskanen T, Kondelin J, Kaasinen E, Sarin AP, Ripatti S, Eriksson JG, Rissanen H, Knekt P, Pukkala E, Jousilahti P, Salomaa V, Palotie A, Renkonen-Sinisalo L, Lepistö A, Böhm J, Mecklin JP, Al-Tassan NA, Palles C, Martin L, Barclay E, Farrington SM, Timofeeva MN, Meyer BF, Wakil SM, Campbell H, Smith CG, Idziaszczyk S, Maughan TS, Kaplan R, Kerr R, Kerr D, Passarelli MN, Figueiredo JC, Buchanan DD, Win AK, Hopper JL, Jenkins MA, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Aaltonen LA, Cheadle JP, Tomlinson IP, Dunlop MG, Houlston RS.

Int J Cancer. 2017 Jun 15;140(12):2701-2708. doi: 10.1002/ijc.30709. Epub 2017 Apr 6.

7.

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.

Madi A, Fisher D, Maughan TS, Colley JP, Meade AM, Tejpar S, Van den Bosch B, Maynard J, Humphreys V, Wasan H, Adams RA, Idziaszczyk S, Harris R, Kaplan RS, Cheadle JP.

J Med Genet. 2017 Aug;54(8):567-571. doi: 10.1136/jmedgenet-2016-104317. Epub 2017 Mar 10.

PMID:
28283541
8.

BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.

Summers MG, Smith CG, Maughan TS, Kaplan R, Escott-Price V, Cheadle JP.

Clin Cancer Res. 2017 Jun 1;23(11):2742-2749. doi: 10.1158/1078-0432.CCR-16-1541. Epub 2016 Nov 4.

9.

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.

Orlando G, Law PJ, Palin K, Tuupanen S, Gylfe A, Hänninen UA, Cajuso T, Tanskanen T, Kondelin J, Kaasinen E, Sarin AP, Kaprio J, Eriksson JG, Rissanen H, Knekt P, Pukkala E, Jousilahti P, Salomaa V, Ripatti S, Palotie A, Järvinen H, Renkonen-Sinisalo L, Lepistö A, Böhm J, Mecklin JP, Al-Tassan NA, Palles C, Martin L, Barclay E, Tenesa A, Farrington S, Timofeeva MN, Meyer BF, Wakil SM, Campbell H, Smith CG, Idziaszczyk S, Maughan TS, Kaplan R, Kerr R, Kerr D, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Taipale J, Cheadle JP, Dunlop MG, Tomlinson IP, Aaltonen LA, Houlston RS.

Hum Mol Genet. 2016 Jun 1;25(11):2349-2359. Epub 2016 Mar 22.

10.

Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.

Jarvis D, Mitchell JS, Law PJ, Palin K, Tuupanen S, Gylfe A, Hänninen UA, Cajuso T, Tanskanen T, Kondelin J, Kaasinen E, Sarin AP, Kaprio J, Eriksson JG, Rissanen H, Knekt P, Pukkala E, Jousilahti P, Salomaa V, Ripatti S, Palotie A, Järvinen H, Renkonen-Sinisalo L, Lepistö A, Böhm J, Meklin JP, Al-Tassan NA, Palles C, Martin L, Barclay E, Farrington SM, Timofeeva MN, Meyer BF, Wakil SM, Campbell H, Smith CG, Idziaszczyk S, Maughan TS, Kaplan R, Kerr R, Kerr D, Buchanan DD, Win AK, Hopper JL, Jenkins MA, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Taipale J, Aaltonen LA, Cheadle JP, Dunlop MG, Tomlinson IP, Houlston RS.

Br J Cancer. 2016 Jul 12;115(2):266-72. doi: 10.1038/bjc.2016.188. Epub 2016 Jun 23.

11.

Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.

Cheng TH, Thompson D, Painter J, O'Mara T, Gorman M, Martin L, Palles C, Jones A, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Giles GG, Pharoah P, Peto J, Cox A, Swerdlow A, Couch F, Cunningham JM, Goode EL, Winham SJ, Lambrechts D, Fasching P, Burwinkel B, Brenner H, Brauch H, Chang-Claude J, Salvesen HB, Kristensen V, Darabi H, Li J, Liu T, Lindblom A, Hall P, de Polanco ME, Sans M, Carracedo A, Castellvi-Bel S, Rojas-Martinez A, Aguiar Jnr S, Teixeira MR, Dunning AM, Dennis J, Otton G, Proietto T, Holliday E, Attia J, Ashton K, Scott RJ, McEvoy M, Dowdy SC, Fridley BL, Werner HM, Trovik J, Njolstad TS, Tham E, Mints M, Runnebaum I, Hillemanns P, Dörk T, Amant F, Schrauwen S, Hein A, Beckmann MW, Ekici A, Czene K, Meindl A, Bolla MK, Michailidou K, Tyrer JP, Wang Q, Ahmed S, Healey CS, Shah M, Annibali D, Depreeuw J, Al-Tassan NA, Harris R, Meyer BF, Whiffin N, Hosking FJ, Kinnersley B, Farrington SM, Timofeeva M, Tenesa A, Campbell H, Haile RW, Hodgson S, Carvajal-Carmona L, Cheadle JP, Easton D, Dunlop M, Houlston R, Spurdle A, Tomlinson I.

Sci Rep. 2015 Dec 1;5:17369. doi: 10.1038/srep17369.

12.

Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.

Phipps AI, Passarelli MN, Chan AT, Harrison TA, Jeon J, Hutter CM, Berndt SI, Brenner H, Caan BJ, Campbell PT, Chang-Claude J, Chanock SJ, Cheadle JP, Curtis KR, Duggan D, Fisher D, Fuchs CS, Gala M, Giovannucci EL, Hayes RB, Hoffmeister M, Hsu L, Jacobs EJ, Jansen L, Kaplan R, Kap EJ, Maughan TS, Potter JD, Schoen RE, Seminara D, Slattery ML, West H, White E, Peters U, Newcomb PA.

Carcinogenesis. 2016 Jan;37(1):87-95. doi: 10.1093/carcin/bgv161. Epub 2015 Nov 19.

13.

Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.

Al-Tassan NA, Whiffin N, Hosking FJ, Palles C, Farrington SM, Dobbins SE, Harris R, Gorman M, Tenesa A, Meyer BF, Wakil SM, Kinnersley B, Campbell H, Martin L, Smith CG, Idziaszczyk S, Barclay E, Maughan TS, Kaplan R, Kerr R, Kerr D, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Dunlop MG, Tomlinson IP, Cheadle JP, Houlston RS.

Sci Rep. 2015 Aug 3;5:12372. doi: 10.1038/srep12372. No abstract available.

14.

A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.

Al-Tassan NA, Whiffin N, Hosking FJ, Palles C, Farrington SM, Dobbins SE, Harris R, Gorman M, Tenesa A, Meyer BF, Wakil SM, Kinnersley B, Campbell H, Martin L, Smith CG, Idziaszczyk S, Barclay E, Maughan TS, Kaplan R, Kerr R, Kerr D, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Dunlop MG, Tomlinson IP, Cheadle JP, Houlston RS.

Sci Rep. 2015 May 20;5:10442. doi: 10.1038/srep10442. Erratum in: Sci Rep. 2015;5:12372. Buchannan, Daniel D [corrected to Buchanan, Daniel D].

15.

Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.

Smith CG, Fisher D, Harris R, Maughan TS, Phipps AI, Richman S, Seymour M, Tomlinson I, Rosmarin D, Kerr D, Chan AT, Peters U, Newcomb PA, Idziaszczyk S, West H, Meade A, Kaplan R, Cheadle JP.

Clin Cancer Res. 2015 Aug 1;21(15):3453-61. doi: 10.1158/1078-0432.CCR-14-3136. Epub 2015 Apr 14.

16.

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DA, de Haan AF, Punt CJ, Koopman M.

Clin Cancer Res. 2014 Oct 15;20(20):5322-30. doi: 10.1158/1078-0432.CCR-14-0332. Epub 2014 Aug 19.

17.

Response.

Smith CG, West H, Harris R, Idziaszczyk S, Maughan TS, Kaplan R, Richman S, Quirke P, Seymour M, Moskvina V, Steinke V, Propping P, Hes FJ, Wijnen J, Cheadle JP.

J Natl Cancer Inst. 2014 Apr 26;106(5). pii: dju087. doi: 10.1093/jnci/dju087. No abstract available.

PMID:
24771876
18.

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.

Smith CG, West H, Harris R, Idziaszczyk S, Maughan TS, Kaplan R, Richman S, Quirke P, Seymour M, Moskvina V, Steinke V, Propping P, Hes FJ, Wijnen J, Cheadle JP.

J Natl Cancer Inst. 2013 Aug 21;105(16):1249-53. doi: 10.1093/jnci/djt183. Epub 2013 Jul 12.

PMID:
23852950
19.

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.

Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP.

Clin Cancer Res. 2013 Aug 1;19(15):4104-13. doi: 10.1158/1078-0432.CCR-12-2581. Epub 2013 Jun 5.

20.

Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.

Smith CG, Naven M, Harris R, Colley J, West H, Li N, Liu Y, Adams R, Maughan TS, Nichols L, Kaplan R, Wagner MJ, McLeod HL, Cheadle JP.

Hum Mutat. 2013 Jul;34(7):1026-34. doi: 10.1002/humu.22333. Epub 2013 May 20.

PMID:
23585368
21.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.

22.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

23.

Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer.

Idziaszczyk S, Wilson CH, Smith CG, Adams DJ, Cheadle JP.

Cancer Genet Cytogenet. 2010 Oct 1;202(1):67-9. doi: 10.1016/j.cancergencyto.2010.04.023. No abstract available.

PMID:
20804925
24.

The APC Variant p.Glu1317Gln predisposes to colorectal adenomas by a novel mechanism of relaxing the target for tumorigenic somatic APC mutations.

Dallosso AR, Jones S, Azzopardi D, Moskvina V, Al-Tassan N, Williams GT, Idziaszczyk S, Davies DR, Milewski P, Williams S, Beynon J, Sampson JR, Cheadle JP.

Hum Mutat. 2009 Oct;30(10):1412-8. doi: 10.1002/humu.21089.

PMID:
19701947
25.

Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis.

Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, Cheadle JP.

Hum Mol Genet. 2009 Jun 15;18(12):2166-76. doi: 10.1093/hmg/ddp149. Epub 2009 Mar 25.

PMID:
19321600
26.

Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3.

Dallosso AR, Dolwani S, Jones N, Jones S, Colley J, Maynard J, Idziaszczyk S, Humphreys V, Arnold J, Donaldson A, Eccles D, Ellis A, Evans DG, Frayling IM, Hes FJ, Houlston RS, Maher ER, Nielsen M, Parry S, Tyler E, Moskvina V, Cheadle JP, Sampson JR.

Gut. 2008 Sep;57(9):1252-5. doi: 10.1136/gut.2007.145748. Epub 2008 May 30.

PMID:
18515411
27.

Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.

Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, Rawstorne E, Colley J, Moskvina V, Frye C, Sampson JR, Wenstrup R, Scholl T, Cheadle JP.

Cancer Res. 2008 Jan 15;68(2):358-63. doi: 10.1158/0008-5472.CAN-07-5733.

28.

Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures.

Goorden SM, van Woerden GM, van der Weerd L, Cheadle JP, Elgersma Y.

Ann Neurol. 2007 Dec;62(6):648-55.

PMID:
18067135
29.

Analysis of inherited MYH/(MutYH) mutations in British Asian patients with colorectal cancer.

Dolwani S, Williams GT, West KP, Newman J, Stock D, Griffiths AP, Best J, Cheadle JP, Sampson JR.

Gut. 2007 Apr;56(4):593. No abstract available.

30.

MUTYH-associated polyposis--from defect in base excision repair to clinical genetic testing.

Cheadle JP, Sampson JR.

DNA Repair (Amst). 2007 Mar 1;6(3):274-9. Epub 2006 Dec 11. Review.

PMID:
17161978
31.

Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+/- mice.

Wilson C, Bonnet C, Guy C, Idziaszczyk S, Colley J, Humphreys V, Maynard J, Sampson JR, Cheadle JP.

Cancer Res. 2006 Aug 15;66(16):7934-8.

32.

Induction of renal tumorigenesis with elevated levels of somatic loss of heterozygosity in Tsc1+/- mice on a Blm-deficient background.

Wilson C, Idziaszczyk S, Colley J, Humphreys V, Guy C, Maynard J, Sampson JR, Cheadle JP.

Cancer Res. 2005 Nov 15;65(22):10179-82.

33.

MutYH (MYH) and colorectal cancer.

Sampson JR, Jones S, Dolwani S, Cheadle JP.

Biochem Soc Trans. 2005 Aug;33(Pt 4):679-83. Review.

PMID:
16042573
34.

Rapid recognition of aberrant dHPLC elution profiles using the Transgenomic Navigator software.

Colley J, Jones S, Dallosso AR, Maynard JH, Humphreys V, Dolwani S, Sampson JR, Cheadle JP.

Hum Mutat. 2005 Aug;26(2):165.

PMID:
16010685
35.

A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma.

Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP.

Hum Mol Genet. 2005 Jul 1;14(13):1839-50. Epub 2005 May 11.

PMID:
15888477
36.
37.

Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas.

Jones S, Lambert S, Williams GT, Best JM, Sampson JR, Cheadle JP.

Br J Cancer. 2004 Apr 19;90(8):1591-3.

38.

Inherited variants in MYH are unlikely to contribute to the risk of lung carcinoma.

Al-Tassan N, Eisen T, Maynard J, Bridle H, Shah B, Fleischmann C, Sampson JR, Cheadle JP, Houlston RS.

Hum Genet. 2004 Jan;114(2):207-10. Epub 2003 Oct 25.

PMID:
14579148
39.

Exposing the MYtH about base excision repair and human inherited disease.

Cheadle JP, Sampson JR.

Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R159-65. Epub 2003 Aug 5. Review.

PMID:
12915454
40.

Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH.

Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, Frayling I, Jordan S, Maher ER, Mak T, Maynard J, Pigatto F, Shaw J, Cheadle JP.

Lancet. 2003 Jul 5;362(9377):39-41.

PMID:
12853198
41.

Inherited defects in the DNA glycosylase MYH cause multiple colorectal adenoma and carcinoma.

Cheadle JP, Dolwani S, Sampson JR.

Carcinogenesis. 2003 Jul;24(7):1281-2; author reply 1283. Epub 2003 May 9. No abstract available.

PMID:
12807739
42.

Mutation analysis in the MECP2 gene and genetic counselling for Rett syndrome.

Gill H, Cheadle JP, Maynard J, Fleming N, Whatley S, Cranston T, Thompson EM, Leonard H, Davis M, Christodoulou J, Skjeldal O, Hanefeld F, Kerr A, Tandy A, Ravine D, Clarke A.

J Med Genet. 2003 May;40(5):380-4. No abstract available.

43.

Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes.

Emmerson P, Maynard J, Jones S, Butler R, Sampson JR, Cheadle JP.

Hum Mutat. 2003 Feb;21(2):112-5.

PMID:
12552557
44.

Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-->T:A mutations.

Jones S, Emmerson P, Maynard J, Best JM, Jordan S, Williams GT, Sampson JR, Cheadle JP.

Hum Mol Genet. 2002 Nov 1;11(23):2961-7.

PMID:
12393807
45.

Temperature modulation of DHPLC analysis for detection of coexisting constitutional and mosaic sequence variants in TSC2.

Antonarakis ES, Sampson JR, Cheadle JP.

J Biochem Biophys Methods. 2002 Apr 18;51(2):161-4.

PMID:
12062115
46.

Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors.

Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP.

Nat Genet. 2002 Feb;30(2):227-32. Epub 2002 Jan 30.

PMID:
11818965
47.

Different combinations of biallelic APC mutation confer different growth advantages in colorectal tumours.

Cheadle JP, Krawczak M, Thomas MW, Hodges AK, Al-Tassan N, Fleming N, Sampson JR.

Cancer Res. 2002 Jan 15;62(2):363-6. Erratum in: Cancer Res 2002 Mar 1;62(5):1579.

48.

Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.

Hodges AK, Li S, Maynard J, Parry L, Braverman R, Cheadle JP, DeClue JE, Sampson JR.

Hum Mol Genet. 2001 Dec 1;10(25):2899-905.

PMID:
11741833
49.

Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas.

Parry L, Maynard JH, Patel A, Clifford SC, Morrissey C, Maher ER, Cheadle JP, Sampson JR.

Br J Cancer. 2001 Oct 19;85(8):1226-30.

50.

Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.

Soucek T, Rosner M, Miloloza A, Kubista M, Cheadle JP, Sampson JR, Hengstschläger M.

Oncogene. 2001 Aug 9;20(35):4904-9.

Supplemental Content

Loading ...
Support Center